Assembly Biosciences: Pay

Assembly Biosciences paid its 3 named executives $5.0M in total in FY2025 (Dec). CEO Jason A. Okazaki was paid $2.5M of that.

Pay$100 in the stock at the end of FY21 → $122
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Jason A. OkazakiChief Executive Officer and President
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
William E. Delaney IV, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)
4 years
Anuj Gaggar, M.D., Ph.D.Chief Medical Officer
FY2025 (Dec)
1 year

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 8 peers with pay on file was $2.5M. The CEO of Assembly Biosciences was paid $2.5M, 2% below the median.

  1. 1CytomX Therapeutics
  2. 2aTYR Pharma
  3. 3Atea Pharmaceuticals
  4. 4Enanta Pharmaceuticals
  5. 5Assembly Biosciences
  6. 6Gossamer Bio
  7. 7Black Diamond Therapeutics
  8. 8Spero Therapeutics
  9. 9Arbutus Biopharma
  10. 10AN2 Therapeutics, Inc.Not disclosed
  11. 11Adverum Biotechnologies, Inc.Not disclosed
  12. 12Aligos Therapeutics, Inc.Not disclosed
  13. 13Caribou BiosciencesNot disclosed
  14. 14Hookipa Pharma Inc.Not disclosed
  15. 15InvivydNot disclosed
  16. 16Kronos Bio, Inc.Not disclosed
  17. 17Precision Biosciences, Inc.Not disclosed
  18. 18Terns Pharmaceuticals, Inc.Not disclosed
  19. 19Vaxart, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.